The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease

• Status: Terminated
• Trial end date: 2005-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an investigator-sponsored research study to evaluate if treatment with HFA-134a beclomethasone (QVAR) has an effect on peripheral (or outer) airway inflammation and airway "remodeling" or scarring in subjects with COPD. Approximately 20 subjects with COPD will participate for approximately 7 weeks, with 10 receiving an active (BDP) inhaler with HFA-134a and 10 receiving a placebo.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Jewish Health
• Treatments: Beclomethasone; Norflurane

Criteria

Inclusion Criteria:

• COPD diagnosis

• FEV1/FVC<70%

• FEV1 50-80% predicted

• Albuterol response of <12% and <200mL or methacholine PC20 > 8mg/mL

• RV > 120% predicted

• DLCO < 80%

• smokers and nonsmokers

• Lower age limit 45 years

Exclusion Criteria:

• Asthma

• Other chronic airway or parenchymal lung disease

• Other comorbid illness (including but not limited to DM, MI or CAD-related intervention in 6 months, neurologic disease, syncope)

• Use of any steroid (oral, IV, nasal, pulmonary) within 12 weeks

• Use of theophylline, leukotriene modifiers within 12 weeks

• Use of long-acting beta-agonists (formoterol, salmeterol) or anticholinergic (tiotropium)